Related Experiment Video
Updated: Oct 26, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Vusolimogene Oderparepvec: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Vusolimogene oderparepvec (TUDRIQEV™; vusolimogene oderparepvec-wtpg) is a genetically modified oncolytic viral therapy that targets cancer cells. It is being developed by Replimune for the treatment of skin malignancies and received its first approval for combination treatment with nivolumab on 6 August 2026 in the USA. The combination of vusolimogene oderparepvec and nivolumab resulted in objective responses in patients with unresectable advanced melanoma after progression with an anti-PD-1 regimen during the IGNYTE phase I/II trial. This article summarises the milestones in the development of vusolimogene oderparepvec leading to this first approval in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1-blocking antibody-based regimen.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Products: Biologics, Biosimilars and Interchangeables
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...